LCT focuses on treatments for diseases that currently have no cure, or are not being well managed. LCT is adopting a strategy of driving its lead product towards the commercialization phase. This market-driven approach means LCT is fully focused on achieving market returns for its shareholders. LCT maintains its discrete product development streams to diversify risk and enhance the company’s global market opportunities.
LCT’s Product Portfolio:
DiabeCell:
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
NeurotrophinCell:
A choroid plexus cell product with the potential to treat neurological diseases such as Huntington’s disease and stroke.
Fac8Cell:
A liver cell product aimed at producing factor 8, a blood clotting agent absent or defective in people suffering haemophilia.
Porcine Tissues:
A range of tissues are now available for licensing / sales from LCT's biocertified pig herd
LCT’s Technology:
- LCT’s technology platform involves the implantation of healthy living cells to replace, repair, or regenerate diseased or damaged organs.
- LCT’s products are based on living cells that are neither synthetically produced nor manufactured by genetic manipulation.
- The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form biocapsules which isolate the transplanted cells from the patient’s immune system but allows the free passage of small nutrient molecules, oxygen and cell products.
- These biocapsules eliminate the need for toxic immunosuppressant drugs.
- The cell capsules are transplanted into the patient for the release of beneficial hormones/insulin/clotting factor.
Mr Simon O’Loughlin, Chairman
Living Cell Technologies
PO Box 3014, Auburn VIC 3123, Australia
Or email to lct@lctglobal.com
